Summary
The product Sibutramine 10 mg, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number GH65721K, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Sibutramine, with a concentration of 15.84 mg, which is significantly above the labeled claim of 10 mg by +58.4%.
The testing process began on 01 August 2022, with the sample received on 09 August 2022, and analysis completed on 12 August 2022. These findings highlight the potential risks associated with consuming such products, as the actual dosage far exceeds the declared amount. This discrepancy underscores the importance of independent testing to protect consumers from unintentional overdosing. This report is intended as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: Sibutramine 10 mg
- Active Ingredient: Sibutramine
- Batch Number: GH65721K
- Expiration Date: Not provided
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #22601
- Testing Ordered: 01 August 2022
- Sample Received: 09 August 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 10 mg (as stated on the label)
- Measured Concentration: 15.84 mg
- Accuracy: 158.4% (+58.4% above label claim)
- Variance: 58.4%
Verification Details
- Verification URL: https://janoshik.com/tests/22601_Q77X5CYSZ5AB
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis confirms a significant variance in the tested product’s dosage, which may pose health risks to consumers. Given the submission and funding by the reseller Opitropin.EU, further third-party testing is advised to assess the consistency of other batches. The excessive dosage found in this sample highlights the importance of stringent quality control measures and regulatory oversight.
Conclusion
The analysis indicates that Sibutramine 10 mg by Unique Pharma contains 15.84 mg, which exceeds the labeled dosage, potentially leading to adverse effects if consumed as per the label. Consumers should exercise caution and seek further verification before use. This report aims to support educational and harm reduction efforts, assisting consumers in making informed choices regarding weight loss supplements.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may introduce biases; however, it still provides valuable insights when critically evaluated alongside independent third-party results. Readers are encouraged to use this information responsibly.
